4
Changes in Ownership
Contineum Therapeutics, Inc. Filed Acc 0001437749-26-005889
Chief Scientific Officer sold 8,124 shares at an average $16.02 ($130,164)
- Chief Scientific Officer acquired 8,124 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Lorrain Daniel S. · Chief Scientific Officer
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-02-24 | Exercise or conversion : show line 1 in the form 10b5-1 | +4,300 | $1.01 | $4,343 | 160,352 | D |
| 2026-02-24 | Sale : show line 2 in the form 10b5-1 | −4,300 | $16.03 | $68,936 | 156,052 | D |
| 2026-02-25 | Exercise or conversion : show line 3 in the form 10b5-1 | +3,824 | $1.01 | $3,862 | 159,876 | D |
| 2026-02-25 | Sale : show line 4 in the form 10b5-1 | −3,824 | $16.01 | $61,228 | 156,052 | D |
| Open-market sales · 8,124 sh · avg $16.02 · $130,164 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-02-24 | Exercise or conversion : show line 5 in the form 10b5-1 Stock Option (right to buy) | −4,300 | 71,130 | D |
| 2026-02-25 | Exercise or conversion : show line 6 in the form 10b5-1 Stock Option (right to buy) | −3,824 | 67,306 | D |
Loading xslF345X05/rdgdoc.xml…